Biopharmaceutical
The latest news about Biopharmaceutical: headlines, AI summaries and the full story from every source.
- PolyPid Advances Toward D-PLEX100 Launch and Extends Financial Runway into 2028
- Disc Medicine Launches $350 Million Public Offering
- Liquidia Shares Rise Nearly 27% Following Settlement with United Therapeutics
- Verastem Oncology Announces $250M Securities Offering
- Acadia Pharmaceuticals Shares Drop Following Disappointing Drug Trial Results
- Xenon Pharmaceuticals Pauses Drug Trial, Sending Shares Down
- Odyssey Therapeutics Extends Financial Runway to 2028 as Clinical Trials Expand
- Ovid Therapeutics Reports Financial Results and Pipeline Updates
- Altimmune Advances Three Liver-Related Clinical Trials Simultaneously
- Roivant Sciences Shares Rise on Positive Mosliciguat Trial Results
- Summit Therapeutics Shares Rise 28% Following Positive Clinical Trial Results for Ivonescimab
- Harbour BioMed Included in Stock Connect, Reflecting Market Recognition
- Incyte Stock Performance Outpaces Market Amid Strong Earnings and Analyst Upgrades
- Apnimed Prices Upsized IPO at $16 per Share, Raising $192 Million
- InflaRx Announces Q2 2026 Earnings Release Date
- SELLAS Life Sciences Shares Rise 12% Amid Investor Anticipation for Key Data
- Inventiva Completes EIB Warrant Restructuring with New Issuance
- PTC Therapeutics Insider Sells Shares Amid Product Revenue Growth to $226 Million
- Cytokinetics CEO Sells Shares Amid Significant Stock Price Increase
- Neurocrine Shares Rise on Strong Sales Growth and Positive Institutional Inflows
- Iovance Biotherapeutics Updates Corporate Presentation with Key Financials and Pipeline Progress
- Pharmazz Inc. to Present Positive Phase III Study Results of Centhaquine (PMZ-2010) at Military Health System Research Symposium
- Ocular Therapeutics Receives Positive FDA Feedback on AXPAXLI
- Rhythm Pharmaceuticals Shares Preliminary Positive Results from Phase 2 Trial for Prader-Willi Syndrome Treatment
- Precigen Secures FDA Orphan Drug Exclusivity for PAPZIMEOS
- NRx Pharmaceuticals Announces Proposed Public Stock Offering
- AtaiBeckley Reports Q1 Financial Results
- Savara Inc. Reports Q1 Financial Results
- Citi Raises Price Target on Lexicon Pharmaceuticals to $3.10
- Immunovant Shares Rise After Positive Clinical Trial Results for Arthritis Treatment
- Truist Lowers Price Target for Insmed Amid Competitive Pressures
- Palisade Bio Reports Q1 2026 Results with Increased R&D Expenses
- Compass Therapeutics Reports Q1 2026 Net Loss of $18.3M
- H.C. Wainwright Upgrades Adlai Nortye's Price Target Amid Positive Outlook on Lead Asset
- Citizens Initiates Coverage on Opus Genetics with Outperform Rating
- Sagimet Biosciences Prices $175M Equity Offering, Shares Rise 30%
- Eli Lilly Agrees to Acquire Ajax Therapeutics for Up to $2.3 Billion in Cash
- Lirum Therapeutics Announces Positive Preclinical Data for LX-101 in Ewing Sarcoma